Copyright
©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer
Lee Chun Park, Ho Sup Lee, Seong Hoon Shin, Seun Ja Park, Moo In Park, Yang Soo Kim, Department of Internal Medicine, Kosin University College of Medicine, Busan 602-703, South Korea
Sung Yong Oh, Hyuk Chan Kwon, Department of Internal Medicine, Dong-A University Hospital, Busan 602-715, South Korea
Jin ho Baek, Department of Internal Medicine, Ulsan University Hospital, Ulsan 682-714, South Korea
Young Jin Choi, Department of Internal Medicine, Busan National University Hospital, Busan 626-770, South Korea
Myoung Joo Kang, Department of Internal Medicine, Busan Paik Hospital, Busan 614-735, South Korea
Author contributions: Park LC and Lee HS collected and analyzed the clinical data, designed the study and wrote the manuscript; Shin SH and Kim YS contributed to the conception of the study; Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ and Kang MJ collected the clinical data; Lee HS was involved in revising the manuscript critically for intellectual content and gave final approval for the submission of the manuscript.
Correspondence to: Ho Sup Lee, MD, Department of Internal Medicine, Kosin University College of Medicine, 34 Amnam-Dong, Seo-Gu, Busan 602-703, South Korea. hs52silver@gmail.com
Telephone: +82-51-9906107 Fax: +82-51-9905820
Received: July 1, 2011
Revised: January 12, 2012
Accepted: February 8, 2012
Published online: March 14, 2012
Revised: January 12, 2012
Accepted: February 8, 2012
Published online: March 14, 2012
Core Tip